- Home
- HAL vs BIIB Comparison
HAL vs BIIB Comparison
Compare HAL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAL
- BIIB
- Stock Information
- Founded
- HAL 1919
- BIIB 1978
- Country
- HAL United States
- BIIB United States
- Employees
- HAL N/A
- BIIB N/A
- Industry
- HAL Oilfield Services/Equipment
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- HAL Energy
- BIIB Health Care
- Exchange
- HAL Nasdaq
- BIIB Nasdaq
- Market Cap
- HAL 28.0B
- BIIB 25.1B
- IPO Year
- HAL N/A
- BIIB 1991
- Fundamental
- Price
- HAL $28.78
- BIIB $157.78
- Analyst Decision
- HAL Strong Buy
- BIIB Buy
- Analyst Count
- HAL 18
- BIIB 25
- Target Price
- HAL $40.50
- BIIB $258.57
- AVG Volume (30 Days)
- HAL 9.3M
- BIIB 1.6M
- Earning Date
- HAL 01-22-2025
- BIIB 10-30-2024
- Dividend Yield
- HAL 2.36%
- BIIB N/A
- EPS Growth
- HAL N/A
- BIIB 10.05
- EPS
- HAL 2.86
- BIIB 11.06
- Revenue
- HAL $23,073,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- HAL $0.97
- BIIB N/A
- Revenue Next Year
- HAL $1.75
- BIIB N/A
- P/E Ratio
- HAL $10.06
- BIIB $14.26
- Revenue Growth
- HAL 0.93
- BIIB N/A
- 52 Week Low
- HAL $27.26
- BIIB $153.62
- 52 Week High
- HAL $41.56
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- HAL 36.17
- BIIB 33.43
- Support Level
- HAL $31.25
- BIIB $158.44
- Resistance Level
- HAL $32.56
- BIIB $162.62
- Average True Range (ATR)
- HAL 0.83
- BIIB 3.19
- MACD
- HAL -0.27
- BIIB 0.90
- Stochastic Oscillator
- HAL 0.65
- BIIB 35.65
About HAL Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the largest pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the past two decades.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.